Search
Volixibat
go.drugbank.com/drugs/DB13914InvestigationalAccording to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments … Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in
Ellagic acid
go.drugbank.com/drugs/DB08846InvestigationalIn pomegranates, there are several therapeutic compounds but ellagic acid is the most active and abundant. Ellagic acid is also present in vegetables. … Ellagic acid is an investigational drug studied for treatment of Follicular Lymphoma (phase 2 trial), protection from brain injury of intrauterine growth restricted babies (phase 1 and 2 trial), improvement
Etidocaine
go.drugbank.com/drugs/DB08987ApprovedEtidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.
AICA ribonucleotide
go.drugbank.com/drugs/DB01700InvestigationalThe drug was first used in the 1980s as a method to preserve blood flow to the heart during surgery and is currently of interest as a potential treatment for diabetes by increasing the metabolic activity … AICAR has been used clinically to treat and protect against cardiac ischemic injury.
Perfluorodecalin
go.drugbank.com/drugs/DB16292Investigationalis under investigation in clinical trial NCT03668665 (Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From
CP-122721
go.drugbank.com/drugs/DB05421ExperimentalCP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.
TC-6987
go.drugbank.com/drugs/DB14854InvestigationalTC-6987 is under investigation in clinical trial NCT01296087 (TC-6987 for the Treatment of Mild to Moderate Asthma).
AM103
go.drugbank.com/drugs/DB05225ExperimentalAM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation … It is being developed by Amira.
Prolease-r-hFSH
go.drugbank.com/drugs/DB05826ExperimentalIt provides patients with long term therapeutic benefit from a single administration rather than multiple injections.